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Utilizing a mutant of neomycin-producing Streptomyces fradiae mutagenized with neutron radiation, 
biotransformation of neomycin into modified compounds was studied. The biotransformation products 
were isolated by ion exchange chromatography and monitored by thin layer chromatography 
bioautography (TLCB). Antibacterial activity of biotransformation products against ten species of 
bacteria including four plant pathogens was tested qualitatively by TLCB and detected quantitatively by 
Oxford cup method. The minimal inhibitory concentration (MIC) of biotransformation products was 
tested by agar diffusion method. Three isolated transformation products had obvious antibacterial 
activity against Staphylococcus aureus, Bacillus subtilis, Proteus vulgaris and Pseudomonas 
solanacarum. At the concentration of 50 µg/ml, the transformation product X had a similar antibacterial 
effect with neomycin but the transformation product Y and Z showed a decreased effect compared to 
neomycin except for P. vulgaris and P. solanacarum. However, the results from MIC analysis 
demonstrated that only the transformation product X maintained the same inhibitory effect with 
neomycin.  
 





Neomycin produced from the fermentation of the 
actinomycete Streptomyces fradiae is a broad spectrum 
water-soluble aminoglycoside antibiotic. Neomycin pos-
sesses excellent effect on streptomycin-resistant bacteria 
(Waksman and Lechevalier, 1949), and was once used 
as a therapeutic agent in clinics for applications including 
ophthalmic, topical and oral administrations (Church, 
1954; Nichols et al., 1973; Poth et al., 1950). However, 
because of the ototoxicity, nephrotoxicity and neuro-
muscular block (Masur et al., 1976; Vital and Prado-
Franceschi, 1969), the clinical employment of neomycin 
through intravenous administrations was limited extremely. 
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(Konde and Monroe,  1955;  Tucker  and  Johnson, 1953) 
and in animal nutrition (Luecke et al., 1951). 
Over time, there had been a few reports on controlling 
plant diseases (Hagborg, 1956; Katznelson and Sutton, 
1951) using neomycin. Recently, we studied the effect of 
neomycin sulfate against four species of plant pathogen 
by pot experiments, and it indicated that the control 
efficiency of neomycin was found to be equivalent to 
streptomycin (He et al., 2008). We further explored the 
action mechanism of neomycin sulfate on Erwinia 
carotovora, a plant pathogen causing soft rot of cabbage 
(Cui et al., 2009). 
Biotransformation of aminoglycosides antibiotics such 
as gentamicin (Testa and Tilley, 1976), ribostamycin 
(Kojima et al., 1973), kanamycin (Cappelletti and Spagnoli, 
1983), sisomicin (Lee et al., 1977) and arbekacin (Hotta 
et al., 1996) has been reported previously. The newly 
modified compounds were not only transformed from the 
antibiotic itself by producing strain (Kojima et al., 1973), 
but   also   obtained  by  mutasynthesis   (Cappelletti  and 




Spagnoli, 1983; Testa and Tilley, 1976; Testa et al., 
1974). Apart from direct fermentation using micro-
organism, the resting cells (Kase et al., 1982), cell free 
extract (Hotta et al., 1996) and enzyme (Haas et al., 
1976) were also employed for biotransformation. Many 
reports about the chemical conversion of neomycin have 
been published in the past decades (Fridman et al., 2003; 
Hainrichson et al., 2005; Hanessian et al., 1978; Toda et 
al., 1983), but only a few papers reported the mutasy-
nthesis of neomycin. Shier et al. (1969) reported the 
semi-synthesis of neomycin from the related aminoc-
yclitols streptamine and 2-epistreptamine transformed by 
a mutant of S. fradiae and thus four new antibiotics was 
obtained. Soon after, Shier et al. (1973) further studied 
the conversion of some analogs of 2-deoxystreptamine to 
antibiotics by 2-deoxystreptamine-negative mutants of S. 
fradiae. In addition, the conversion from three 
phosphoamido-neomycins to neomycin was also reported 
by Majumdar and Majumdar, (1970). However, up till 
now, no information about the direct biotransformation 
from neomycin by its producer or mutant of S. fradiae is 
available. In the present study, a mutant of S. fradiae 
mutagenized with neutron radiation was used for conver-
sion and neomycin itself was used as the substrate. Our 
aim is to obtain the new derivatives of neomycin with 
antibacterial activity so as to provide more candidate 
compounds for medical or agricultural application. 
 
 
MATERIALS AND METHODS 
 
Isolation of S. fradiae mutant mutagenized with neutron 
radiation 
 
Three growth culture of 7-day-old S. fradiae spores grown on 
Gause No.1 agar medium slant were washed with 30 ml phosphate 
buffer (0.1 mol/L, pH 7.0) and incubated for 30 min with reciprocal 
shaking at 150 rpm. After centrifuging at 4000 rpm and discarding 
the supernatant, the spores were suspended with 2 ml sterile water 
and added to 8 ml Gause’s liquid medium. The suspension was 
incubated for 3 h until proper germination of the spores. An aliquot 
of spore suspension (0.5 ml) was transferred into test tube (1.0 × 
7.5 cm) and radiated at the dose of 400 Gy for 4 h with neutron 
accelerator in 720 Institute of Sichuan University, China. Four 
replicates of radiation treatment were applied. The radiated spore 
suspension was diluted with 4.5 ml sterile water. Petri plates 
containing Gause No.1 agar were inoculated with survivors of the 
radiation treatment, incubated for 3 days at 28°C until individual 
colony occurred, and the spore suspension without radiation 
treatment was served as the control. The individual colonies were 
re-inoculated to fresh Gause No.1 agar plates for another 3 days 
incubation. The occurred colonies punched with a puncher (6 mm 
diameter) were placed on the Gause agar bioassay plates seeded 
Staphylococcus aureus and incubated at 28°C for 18 h. The plates 
were screened for a colony that showed no inhibition zone against 
S. aureus. The procedures were repeated more than three times 
until the stable mutant of S. fradiae was obtained.  
 
 
Culture conditions of the mutant 
 





radiation was maintained on a Gause’s No.1 slant at 4°C and was 
subcultured at monthly intervals. A well sporulated slant culture (7 
days old) was grown in a seed medium consisting (g/L) of: Soluble 
starch, 20 g; KNO3, 1 g; K2HPO4, 0.5 g; MgSO4, 0.5 g; NaCl, 0.5 g; 
FeSO4, 0.01 g; for 3 days at 36°C on a reciprocal shaker. The 




Detection of transformation products from small-scale 
fermentation by RP-HPLC 
 
Transformation fermentation  
 
Inocula prepared in seed culture were used at 2.5% (v/v) for 
fermentations in a 100 ml Erlenmeyer flask containing 30 ml of 
Gause medium as described above. Neomycin sulfate used for 
biotransformation was supplied by Sichuan Long March Pharma-
ceutical Corporation, Chengdu, China. Neomycin was added at 600 
µg/ml after 72 h of fermentation. Four treatments including 
neomycin aqueous solution, the medium without neomycin and 
inoculum, the medium only with inoculum and the medium only with 
neomycin were used as the controls. The equivalent of neomycin or 
inoculum was applied at each treatment as the transformation 
fermentation. The transformation fermentation together with other 
four controls was simultaneously carried out on a reciprocal shaker 
at 150 rpm for 120 h at 36°C.  
Derivatization reagent, potassium borate buffer (0.2 mol/L) was 
prepared by dissolving 12.37 g boric acid in 980 ml of deionized 
water and adjusting the pH to 10.4 with 10 mol/L potassium 
hydroxide solution, followed by dilution to 1 L. OPA reagent was 
prepared by dissolving o-phthalaldehyde (100 mg) in 2 ml of 
methanol, followed by addition of 2-mercaptoethanol (1 ml). The 
solution was gently mixed until complete decolorization occurred. 
Potassium borate buffer (100 ml) was then added with vigorous 
stirring. The solution was placed in brown bottle at 4°C, and used 
within 5 days. 
 
 
Samples preparation and pre-column derivatization  
 
The fermentation broth of different treatment was centrifuged at 
10000 rpm, 10°C for 10 min. The supernatant was filtered to 
remove debris through reduced pressure. The resulting solution 
and neomycin aqueous solution were stored at 4°C for less than 2 
days before analysis by reversed-phase high-performance liquid 
chromatographic (RP-HPLC). A 0.2 ml aliquot of each resulting 
solution or neomycin aqueous solution was added to 0.2 ml of OPA 
reagent. The mixture was shaken sufficiently and allowed to react 
for 10 min at 30°C water bath. After the reaction, the mixture was 
added to 0.8 ml isopropanol and the resulting solution was shaken 






Chromatography was carried out on Shimadzu LC system and 
SPD-M20A diode array detector (Shimadzu Corporation, Kyoto, 
Japan). Data integration and processing were performed with 
LCSolution software (Shimadzu, Japan). The HPLC column used 
was an ODS-SP packed C18 (4.6 mm i.d. × 150 mm length, 5 µm, 
Inerstil, Tokyo, Japan). The mobile phase was methanol-water 
(65:35, v/v). This mobile phase was filtered through a 0.45 µm 
membrane filter and degassed prior to use. The flow rate was 
performed at 1 ml/min and the UV detector set at a wavelength of 
334 nm. Aliquots of 10 µl of each derivative sample were injected 





Large scale fermentation and isolation of biotransformation 
products 
 
Inocula prepared in seed culture were used at 5% (v/v) for 
fermentations in a 500 ml Erlenmeyer flask containing 200 ml of a 
medium with the following composition: Peptone, 6 g; casein, 4 g; 
yeast extract powder, 3 g; beef powder, 1 g; and glucose, 2 g. 
Neomycin was added at 600 µg/ml after 72 h of fermentation. The 
transformation fermentations were carried out on a reciprocal 
shaker at 150 rpm for 120 h at 36°C. Occasional checking of the 
flask to drop adhering cells into medium was necessary during the 
whole process. 
The fermentation broth (3 L) was centrifuged and filtered as 
above. The supernatant was adjusted to pH 7.5 with aqueous 
ammonia and passed through a column (3.5 × 40 cm) containing 
100 ml of Amberlite FPC-3500 cation exchange resin in NH4
+
 form 
(Rohm and Haas Co., Philadelphia, Pennsylvania, USA). After 
washing with adequate deionized water, the resin was eluted with 2 
mol/L ammonium hydroxide. The eluates were concentrated to 
dryness under reduced pressure at 50°C. The dried material was 
dissolved in deionized water to a desired concentration and applied 
to anion exchange resin Amberlite FPA-90Cl (Rohm and Haas Co., 
USA) for decolorization. The decolored eluates were passed 
through a column (2.0 × 30 cm) containing 50 ml of Amberlite CG-
50 cation exchange resin (type I, 100-200 mesh, Rohm and Haas 
Co., USA) and washed with deionized water. The CG-50 resin was 
eluted with a linear gradient of 0.05 to 0.5 mol/L ammonium 
hydroxide. Fractions were collected with 15 ml in each tube. Each 
fraction was concentrated to a range of 0.5 - 1.0 ml and then 
monitored using thin layer chromatography bioautography (TLCB). 
Similar fractions were combined and evaporated under reduced 
pressure to yield crude preparations. The crude preparations were 
further chromatographically separated on a smaller CG-50 resin 
column (1.0 × 30 cm) and eluted with a linear gradient of 0.01 to 0.2 
mol/L ammonium hydroxide. Fractions were collected with 5 ml in 
each tube and monitored as above. 
 
 
Bioautography of fractions from ion exchange 
chromatography 
 
The high-performance thin layer chromatography (HPTLC) plates 
(5.0 × 6.5 cm, cut from 5.0 × 20 cm precoated silica gel plates) 
were pre-developed to the top with chloroform-methanol-25% 
ammonium hydroxide (2:3:2) as developing solvent which was an 
improvement based on the published report (Baud et al., 1977; 
Testa and Tilley, 1975). The pre-developed plates were dried 
completely at 100°C and then spotted with fractions eluted from 
Amberlite FPC-3500 or Amberlite CG-50 resin column. 
Simultaneously, neomycin sulfate diluted solution was served as 
the control. The spotted plates were dried naturally and 
redeveloped with the same developing solvent up to the height of 
5.5 cm. The developed plates were dried at 60°C for 1 h and placed 
in 90 mm Petri dishes with face upward. After sterilizing under UV 
light for 20 min, the plates in Petri dishes were covered with 20 ml 
of the sterilized beef extract peptone agar medium (beef extract 
0.03%, peptone 1%, NaCl 0.05% and agar 2%) mixed S. aureus, a 
sensitive Gram-positive bacterium to neomycin. The plates were 
incubated overnight at 36°C and the surface of the medium was 
then sprayed with triphenyltetrazolium chloride (TTC) solution 
(0.2%). The plates were incubated for 30 min. White inhibition 
zones were visible against a red background. 
 
 
Antibacterial activity of biotransformation products by 
bioautography 
 
Antibacterial  activity  of  three  purified  biotransformation  products 




against 10 species of bacteria including S. aureus was tested by 
bioautography method as above. The tested bacteria including S. 
aureus, Bacillus subtilis, Escherichia coli, Pseudomonas 
aeruginosa, Proteus vulgaris, Enterobacte cloacae (kindly provided 
by Sichuan Industrial Institute of Antibiotic, China) and four 
phytopathogenic bacteria (Xanthomonas oryzae, Xanthomonas 
axonopodis, Erwinia carotovora and Pseudomonas solanacarum, 
kindly provided by Institute of Plant Protection, Sichuan Academy of 
Agricultural Science, China).  
 
 
Antibacterial activity of biotransformation products by Oxford 
cup method 
 
The antibacterial activity of transformation products of neomycin 
sulfate against 10 bacteria was evaluated by the modified Oxford 
cup method (Carlson and Douglas, 1948) and the inhibition zone 
diameters were measured. Beef extract peptone agar media was 
used for bacterial culture. One milliliter (1 ml) of an 18 h old culture 
was added to 60 ml of the medium, and 20 ml of this culture was 
shaked and poured into sterile Petri dishes. After the solidification 
of the agar medium, the sterile stainless steel cylinders (6 × 10 mm) 
were placed on the surface of the seeded agar and filled with 100 µl 
of the tested samples at 50 µg/ml. The plates were incubated at 
36°C for 24 h. 
 
 
Minimal inhibitory concentration (MIC) of biotransformation 
products 
 
The agar diffusion method was used to evaluate the MIC of tested 
materials. An overnight culture grown in beef extract peptone broth 
was diluted to approximately 10
5
 CFU/ml in sterile water. The 
diluted bacterial suspension was inoculated onto agar plates 
containing serial two-fold dilutions of neomycin and its 
transformation products at a final concentration ranging from 16 to 
0.0156 µg/ml (Dienstag and Neu, 1972). The MIC was defined as 
the lowest concentration of antibiotic preventing visible organism 
growth after incubation for 16 to 18 h at 36°C. 
 
 
RESULTS AND DISCUSSION 
 
HPLC analysis of transformation product 
 
Directed analysis of biotransformation fermentation broth 
by reversed-phase high performance liquid chromate-
graphy (RP-HPLC) showed the mutant of S. fradiae had 
the ability to convert neomycin to new derivative of 
neomycin (Figure 1). In the medium control (Figure 1A) 
and the control of medium only with inoculum (Figure 1B) 
no distinct peak was found except the reagent peaks. 
The peak area and peak height of neomycin (I) in 
aqueous solution (Figure 1C) and in medium without 
inoculum (Figure 1D) were similar and the retention time 
was at 15.073 and 14.944 min, respectively. In transfor-
mation treatment (Figure 1E), the area and height of 
neomycin peak (I) decreased obviously compared with 
two controls added with neomycin. Another new small 
peak (II) at the retention time 21.485 was detected, but 
no corresponding peak was found for the other four 
controls. This result implies that neomycin may be 
degrades mostly due  to  providing  C, N  and  energy  for  







Figure 1. RP-HPLC of the transformation product from culture broth 
of Streptomyces fradiae mutant. A. medium; B. medium with 
inoculation; C. neomycin in aqueous solution; D. medium with 
addition of neomycin but no inoculation, E. transformation of 





growth (Perlman and Sebek, 1971), and transformation of 
neomycin to its analog also occurs. 
Detection of biotransformation products of aminogly-
coside antibiotics from culture broth by HPLC was 
seldom reported previously (Cappelletti and Spagnoli, 
1983). Although thin layer chromatography (TLC) and 
high-voltage paper electrophoresis were also used in 
monitoring modification product of arbekacin from 
reaction mixture (Hotta et al., 1996), in most cases, 
detection of biotransformation products were performed 
after isolating and purifying the fermentation broth by ion 
exchange chromatography. The usual methods for identi-
fying transformation products includes: TLC (Cappelletti 
and Spagnoli, 1983; Kojima and Satoh, 1973; Takeda et 
al., 1978; Testa and Tilley, 1975, 1976), paper 
chromatography (Majumdar and Majumdar, 1970; Shier 
et al., 1973) and preparative paper chromatography 
(Kojima et al., 1975, Shier et al., 1969, 1973). 
HPLC analysis of culture broth could provide a rapid 
detection for determining whether the transformation 
occurs or not. However, we found the pre-column derivation 
reaction of neomycin with OPA plus 2-mercaptoethanol 
was significant interfered by culture broth. When organic 
ingredients such as peptone, beef extract and yeast 
powders were supplemented to the culture medium, the 
neomycin peak could not be monitored by HPLC (data 
not shown). It is not clear whether other derivation 
reagents such as 2,4,6-trinitrobenzenesulfonic acid could 
be affected by organic ingredients (Cappelletti and 
Spagnoli, 1983). When Gause’s No. 1 medium was used 
for transformation of neomycin, the derivation reaction of 
culture broth with OPA was normal and stable. However, 
Gause’s No. 1 medium can only provide limited nutrients 
for growth. Thus nutrient medium which contained natural 




Isolation and identification of modified neomycin 
 
In order to isolate the modified neomycin compounds, a 
large scale transformation culture was carried out and 
followed by a column chromatography using Amberlite 
FPC-3500 (NH4
+
 type, former IRC-50) and Amberlite CG-
50 (NH4
+
 type). From 3 L preparative transformation of 
neomycin (1.8 g substrate), 1.59 g of crude product was 
isolated after being chromatographed by Amberlite FPC-
3500 resin and decolored by Amberlite FPA-90 (Cl- type) 
resin. The result of bioautography of partial fractions 
collected from chromatography by Amberlite CG-50 resin 
(1.59 g crude product was loaded on 2.0 × 30 cm 
column) is shown in Figure 2. Fractions 16 - 25 were 
eluted with 0.05 mol/L ammonium hydroxide. Two 
distinctive transformation product spots were observed at 
fractions 18 - 20 (Rf 0.72) and fractions 21 - 23 (Rf 0.49) 
respectively (Figures 2A and B), despite incomplete 
isolation with neomycin substrate (Rf 0.37). Among 
fractions   26 - 35    eluted    with    0.1 mol/L   ammonium  






Figure 2. Bioautography of neomycin (CK) and the fractions isolated form Amberlite CG-50 cation ion 
exchange chromatography (2.0 × 30 cm) against Staphylococcus aureus. A. fractions 16 - 20; B. fractions 




hydroxide, fractions 28 - 32 (Rf 0.60) also showed a clear 
new spot which was different from authentic neomycin 
(Figure 2C and D). Fractions 46 - 50 and 66 - 70 were 
eluted with 0.15 and 0.2 mol/L ammonium hydroxide, 
respectively. Fractions 46 - 50 were obviously different 
from the authentic neomycin but could not be considered 
a single compound. Fractions 66 - 70 showed a higher 
polar spot than neomycin (short movement) except for 
another less polar spot (long movement). To obtain 
purified transformation products, the pooled fractions of 
16 - 19 (I), 20 - 23 (II) and 24 - 35 (III) from Amberlite CG-
50 column (2.0 × 30 cm) were rechromatographed by 
Amberlite CG-50 column (1.0 × 30 cm) and monitored by 
bioautograph (Figure 3). From the mixture I (16 - 19), the 
fractions 38 - 45 showed similar movement, so these 
fractions were combined and concentrated to dry (17.8 
mg, designated compound X). From the mixture II (20 - 
23), the fraction 18 and 19 were combined (4.3 mg, 
designated compound Y) and the pooled fractions 46 - 52 
from the mixture III (24 - 35) were obtained and 
designated compound Z (15.6 mg). The lower biotrans-
formation rate of neomycin is similar to the result of 
transformation of arbekacin reported by Hotta et al. 
(1996). In addition, Perlman and Sebek, (1971) had 
pointed that the nearly complete degradation of anti- 
biotics by microbial attack in some cases could lead 
extreme low transformation to modified compound. 
Column chromatography with weakly acidic ion-exchange 
resin was a common method used for isolating amino-
glycoside antibiotics (Awata et al., 1983; Claes et al., 
1974; Majumdar and Majumdar, 1970). Moreover, the 
strongly basic anion exchange resin (Inouye and Ogawa, 
1964; Maehr and Schaffner, 1964), dextran gels (Berdy 
et al., 1977), cellulose powder (Rinehart et al., 1960) and 
silica gel (Lee et al., 1977) were also applied for column 
chromatography. In the present study, cation exchange 
resin Amberlite FPC-3500 (former IRC-50) was used to 
isolate fermentation broth. After elution by 2 mol/L 
ammonium hydroxide, the eluted solution contained 
pigment heavily,  and  so  we  loaded  the  colored  crude  






Figure 3. Bioautography of neomycin (CK) and the fractions 
isolated from Amberlite CG-50 cation ion exchange 
chromatography (1.0 × 30 cm) against Staphylococcus aureus. I-A, 
fractions 38 - 42 and I-B, fractions 43 - 65: isolated from the pooled 
fractions 16 - 19 (see Figure 2). II-A, fractions 18 - 22 and II-B, 
fractions 23 - 27: isolated from the pooled fractions 20 - 23 (see 
Figure 2). III-A, fractions 43-47 and III-B, fractions 48-52: isolated 





product on Amberlite FPA-90 (Cl
- 
type) column for 
decolorization through which the decolored rate could 
reach 90%. Leach et al. (1951) have reported the 
decolorization with carbon chromatography (Darco G-60) 
for commercial preparation neomycin sulfate, but the 
yield over the carbon column was only 57%. When the 
decolored crude product was applied on Amberlite CG -
50 column, the concentration of eluted solvent (ammo-
nium hydroxide) was very important for good separation. 
According to previous published reports (Hotta et al., 
1996; Kojima et al., 1973, 1975), we carried out two step 
isolation with Amberlite CG-50 resin at different eluted 




Antibacterial activity of transformation products 
 
Thin-layer chromatography bioautography (TLCB) is quite 
simple, inexpensive and a reliable method for identifi-
cation of active compounds; it is especially suitable for 
sensitive biological detection (Ramírez et al., 2003; 
Rosner and Aviv, 1980; Salisbury et al., 1989). We 
modified the method described by Salisbury et al. (1989), 
not placing TLC plate face down on the surface of agar 
for 15 min and then removing TLC plate, but directly 
distributing the agar mixed inoculum over TLC plate. Our 
method is more simple and easy to operate. 
Antibacterial activity against six human pathogen 
bacteria and four plant pathogen bacteria of neomycin’s 
biotransformation products (compound X, Y and Z) were 
tested by TLCB. The results showed E. coli, P. aeruginosa, 
E. cloacae, X. oryzae, X. axonopodis and E. carotovora 
were not sensitive to neomycin and its transformation 
products, but S. aureus, B. subtilis, P. vulgaris and P. 
solanacarum were observed to be inhibited (Figure 4). At 
the condition of same sample application, the inhibitory 
spots of neomycin and its transformation products 
against P. solanacarum were more obvious than against 
the other three plant pathogen bacteria (Figure 4D). 
Quantitative detection of antibacterial activity was 
carried out by Oxford cup method and the result was 
showed in Table 1. Compound X displayed a similar 
antibacterial activity with neomycin sulfate. The difference 
of the diameter of inhibitory zone between compound X 
and neomycin sulfate was not significant except for E. 
coli. The antibacterial activity of compound Y and Z 
against S. aureus, B. subtilis and E. coli was lower than 
neomycin sulfate, but no evident difference was observed 
among the tested materials against P. vulgaris. E. 
cloacae and P. aeruginosa showed insensitive to 
neomycin and its transformation products at the test 
concentration (50 µg/ml). For plant pathogens, three 
transformation products and neomycin sulfate had the 
similar inhibitory effect against P. solanacarum at the test 
concentration, but compound Y and Z showed no 
inhibitory effect against X. oryzae, X. axonopodis and E. 
carotovora.  The  present  work  merely  tested   the  anti- 






Figure 4. Bioautography of neomycin (CK) and transformation products (X, Y and Z) against 





Table 1. Antibacterial activity of neomycin and its biotransformation products by Oxford cup method. 
 
Bacteria 
Diameter of inhibitory zone (mm) 
Neomycin sulfate 
a
 Compound X 
a
 Compound Y 
a
 Compound Z 
a
 
Human pathogen     
Staphylococcus aureus 15.3 ± 0.6 a 15.0 ± 1.0 a 11.3 ± 0.6 b 8.8 ± 1.0 c 
Bacillus subtilis 16.3 ± 1.2 a 17.3 ± 1.2 a 12.2 ± 0.8 b 10.3 ± 0.6 c 
Escherichia coli 10.3 ± 0.6 a 9.2 ± 0.3 b 8.7 ± 0.6 b 7.3 ± 0.6 c 
Proteus vulgaris 14.0 ± 1.0 a 14.8 ± 1.2 a 14.5 ± 0.9 a 14.5 ± 1.3 a 
Enterobacter cloacae - 
b
 - - - 
Pseudomonas aeruginosa - - - - 
Plant pathogens     
Pseudomonas solanacarum 14.0 ± 1.0 a 15.2 ± 0.8 a 14.8 ± 1.2 a 14.5 ± 1.3 a 
Xanthomonas oryzae 8.3 ± 0.6 a 8.7 ± 1.2 a - - 
Xanthomonas axonopodis 9.3 ± 0.6 a 8.7 ± 0.6 a - - 
Erwinia carotovora 12.2 ± 1.8 a 11.0 ± 1.3 a - - 
 
The data was showed as mean ± SD with triplicate at each treatment. Values followed by the same letter in the same row were not 
significant according to the Least Significant Difference Test at 5% level. 
a
 The concentration of tested materials was 50 µg/ml and 
b
 
No inhibitory zone. 









Neomycin sulfate Compound X Compound Y Compound Z 
Human pathogens 
Staphylococcus aureus 0.25 0.25 4 4 
Bacillus subtilis 0.25 0.25 2 2 
Escherichia coli 1 1 8 8 
Proteus vulgaris 0.25 0.25 4 4 
Enterobacter cloacae > 16 > 16 > 16 > 16 
Pseudomonas aeruginosa > 16 > 16 > 16 > 16 
Plant pathogens 
Pseudomonas solanacarum 2 2 16 16 
Erwinia carotovora 4 4 > 16 > 16 
Xanthomonas oryzae > 16 > 16 > 16 > 16 




bacterial activity against 10 strains which was not suffi-
cient for reflecting the biological activity of transformation 
products. Accordingly, more pathogen bacteria need to 
be detected further. 
The difference of antibacterial activity between neo-
mycin and the transformation products was detected 
further by MIC analysis. The results of Table 2 showed 
that the transformation product X still had the same 
antibacterial activity with neomycin, but the transfor-
mation product Y and Z were found a lower inhibitory 
effect than neomycin against all tested bacteria. Our 
previous study in pot experiment showed that the highest 
control efficacy of neomycin was observed at X. axonopodis 
(He et al., 2008). However, from in vitro antibacterial 
experiment in the present study, P. solanacarum was the 
most sensitive plant pathogen bacteria and E. carotovora 
was the next. This difference is most likely related to the 
absorption and translocation of neomycin in plant 
(Pramer, 1953) because of different application method in 
pot experiment. We found that the MIC of neomycin and 
transformation product X against E. carotovora was 4 
µg/ml, which is in agreement with our previous study (Cui 
et al., 2009). From antibacterial activity analysis, it is 
suggested that the transformation product X deserves 
further research such as structure analysis through 
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